Three thousand new cases of Mantle Cell Lymphoma (MCL), a form of blood cancer, appear in the United States each year. With a median survival span of only five to seven years, according to the Leukemia and Lymphoma Society, this disease is devastating, and new therapies are sorely needed.

New research shows that women who regularly use pain relief medications, particularly aspirin, have a decreased risk of serous ovarian cancer - an aggressive carcinoma affecting the surface of the ovary. The study published in Acta Obstetricia et Gynecologica Scandinavica reports that non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), paracetamol (acetaminophen), or other analgesics did not decrease ovarian cancer risk.

An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and researchers report in the Journal of the American Medical Association.

Scientists at USC have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug-resistant.

A new type of antibiotic can effectively treat an antibiotic-resistant infection by disarming instead of killing the bacteria that cause it. Researchers report their findings in the October 2 issue of mBio®, the online open-access journal of the American Society for Microbiology.

Using biological markers - genetic characteristics that are associated with some patients with breast cancer - can increase the success rate of clinical trials for breast cancer drugs by almost 50 per cent, says new research from the University of Toronto Mississauga.

All major clinical trials now include disclosures detailing who funded the study to ensure transparency. However, is it possible that this transparency is actually hurting research? One might assume that the methodological rigor of the study matters to physicians more than the disclosure.